BIVI (BioVie) Buyback Yield %: -60.82 (As of Jul. 12, 2026)


BIVI BioVie Inc BIVI
34 GF Score
Price $2.28
! 1 Warning Sign
View Full Analysis

What is BioVie Buyback Yield %?

BioVie BIVI +1.34% 34 Buyback Yield % is -60.82 as of Jul. 12, 2026. GuruFocus rates BIVI with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 742 Biotechnology companies, BioVie ranks worse than 85.85% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

BioVie's current buyback yield was -60.82%.

BioVie Buyback Yield % Historical Data

* Premium members only.

The historical data trend for BioVie's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVie Buyback Yield % Chart

BioVie Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.13 -51.06 -35.29 -112.15 -88.54

BioVie Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -86.37 -88.54 -166.71 -119.55 -99.05

BIVI vs CYCN, LNAI, CTXR: Buyback Yield % Comparison

For the Biotechnology subindustry, BioVie's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioVie Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVie's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where BioVie's Buyback Yield % falls into.


BIVI
34GF Score
BioVie Inc BIVI
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioVie Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

BioVie's Buyback Yield for the fiscal year that ended in Jun. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 15.675) / 17.7045
=-88.54%

BioVie's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 10.458) / 10.5588
=-99.05%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -60.82 mean?
BioVie (BIVI) has a Buyback Yield % of -60.82 as of Jul. 12, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on BioVie and its competitors. According to the industry distribution chart, BioVie ranks #637 out of 742 companies in the Biotechnology industry, placing it in the top 85.8%.
Is BioVie's Buyback Yield % too high?
BioVie's current Buyback Yield % is -60.82. Based on the distribution chart, BioVie ranks #637 out of 742 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioVie has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does BioVie's Buyback Yield % compare to CYCN and LNAI?
According to the Biotechnology industry distribution chart, BioVie ranks #637 out of 742 companies for Buyback Yield %. This places BioVie in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on BioVie and its competitors. BioVie's current Buyback Yield % is -60.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVie stock overvalued right now?
BioVie (BIVI) has a current Buyback Yield % of -60.82. The current Buyback Yield % is -60.82. BioVie's overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For BioVie (BIVI), the current Buyback Yield % is -60.82 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVie Business Description

Address 680 W Nye Lane, Suite 204, Carson, NV, USA, 89703
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
34GF Score

Get the complete analysis for BIVI

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.28
Price